Search Abstracts Program

Session 68   Poster Session Immune Reconstitution with Antiretroviral Chemotherapy 4:30-6:30 pm 4E-F

Click on the to view the poster for an abstract.

479-M.	Increased Initial Anti-HIV Activity and Decreased Initial CD4 T-Cell Response with Efavirenz (EFV) Added to Ritonavir (RTV) and Saquinavir (SQV) Treatment C. L. Cooper*1, C. Fraser2, I. Seguin1, Y. Khaliq1, D. Cote1, N. Hawley-Foss1, A. D. Badley1, G. E. Garber1, K. Gallicano1, J. B. Angel1, and D. W. Cameron1 1Ottawa Hosp. Res. Inst., Univ. of Ottawa, ON, Canada and 2Imperial Coll. Sch. of Med., London, UK Add to Itinerary
480-M.	Continued CD4+ T-Cell Count Gains in Patients with 4 Years of Suppressed Viral Load on HAART P. Hunt*1, S. G. Deeks1, B. Rodriguez2, H. Valdez2, S. B. Shade1, 3, D. Abrams1, 3, M. Krone1, T. Neilands1, M. Lederman2, and J. Martin1 1Univ. of California, San Francisco; 2Case Western Reserve Univ., Cleveland, OH; and 3Community Consortium, San Francisco, CA Add to Itinerary
481-M.	First Phase Immune Restoration Is Comparable in Antiretroviral (ARV) Naïve Subjects Receiving a Protease Inhibitor (PI) or Triple-NRTI-Based ARV Regimen A. Landay*1, J. Spritzler2, H. Kessler1, D. Mildvan3, M. Pu3, L. Fox4, D. Kuritzkes5, and M. Lederman6 for the 5014 Team. 1Rush Med. Coll., Chicago, IL; 2Statistical and Data Analysis Ctr., Harvard Sch. of Pub. Hlth., Boston, MA; 3Beth Israel Med. Ctr., New York, NY; 4DAIDS, NIAID, NIH, Bethesda, MD; 5Univ. of Colorado Hlth. Sci. Ctr., Denver; and 6Case Western Reserve Univ., Cleveland, OH Add to Itinerary
482-M.	HAART Efficacy in Restoring HIV-Induced Abnormal B-Lymphocyte Function M. A. Jacobson*, H. Khayam-Bashi, D. Black, and V. Ng Univ. of California, San Francisco and San Francisco Gen. Hosp. Add to Itinerary
483-M.	Decreased Replication Capacity and R5(NSI) Phenotype, but not Host Factors, are Associated with a CD4/VL Discordant Response to PI-Based HAART S. Sufka*1, T. Wrin2, S. A. Fiscus3, D. Patel1, H. King2, N. Hellmann2, and C. Hicks1 1Duke Univ. Med. Ctr., Durham, NC; 2ViroLogic, Inc., South San Francisco, CA; and 3Univ. of North Carolina, Chapel Hill Add to Itinerary

---